AIM
AVIR icon

Aigen Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

Aigen Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,977
Closed -$91K – 564
2021
Q4 		$91K Buy
+10,977
New +$171K 0.01% 997

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aigen Investment Management's AVIR Position: Q1 2022 in Review

Aigen Investment Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 10,977 shares — an estimated $91K sold.

Aigen Investment Management first reported a position in AVIR in Q4 2021 and held it in 1 quarter. The position peaked at $91K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Aigen Investment Management reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Aigen Investment Management sold 10,977 Atea Pharmaceuticals shares in Q1 2022, an estimated $91K.
  • Aigen Investment Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Aigen Investment Management's Atea Pharmaceuticals position peaked at $91K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Aigen Investment Management's 13F filing for Q1 2022, filed 5 May 2022.